Migraines are not just ordinary headaches. They are complex neurological conditions that significantly impact the quality of life for millions of sufferers globally. Characterized by debilitating pain, sensitivity to light and sound, nausea, and vomiting, migraines are more than a mere inconvenience; they represent a severe healthcare challenge.
Amidst the myriad of treatments available, from over-the-counter medications to prescription drugs, one alternative therapy has been drawing increasing attention: medical cannabis (MC). This comprehensive review delves into the evidence surrounding the use of MC in treating migraines in adults, exploring its potential as a safer, more effective treatment option.
Understanding Migraines: More Than Just a Headache
Migraines are recognized as a primary headache disorder, often presenting with a unique set of symptoms such as unilateral pulsating pain, photophobia, phonophobia, and sometimes aura—neurological symptoms that precede the headache. The global prevalence of migraine is staggering, with estimates suggesting that it affects 1 billion people worldwide, making it the second leading cause of disability among individuals under 50 years of age.
The impact of migraines extends beyond physical symptoms, affecting social relationships, employment, and overall well-being. Traditional treatment options range from NSAIDs and triptans to more invasive procedures like nerve decompression surgery. However, the variability in treatment response and potential adverse effects have led patients and healthcare providers to explore alternative therapies, including MC.
The Shift Towards Medical Cannabis: A Historical Perspective
The use of cannabis for medicinal purposes dates back centuries, with documented use for treating various ailments. However, its application for migraine relief has gained prominence only in recent decades, fueled by anecdotal reports and a growing body of research. Cannabis contains over 100 cannabinoids, with Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) being the most studied for their medicinal properties. Unlike Δ9-THC, CBD does not produce psychoactive effects, making it an area of interest for medical research.
Evaluating the Evidence: A Comprehensive Review
A team of researchers from the University of Arizona conducted a thorough review of the available literature on the effectiveness and safety of MC in treating adult migraines. Their search across multiple databases yielded 12 studies involving 1,980 participants from Italy and the USA.
The evidence indicated that MC could significantly reduce nausea and vomiting, decrease the number of migraine days, and lower the frequency of migraine headaches per month. Notably, MC was found to be 51% more effective in reducing migraine frequency than non-cannabis products in some cases.
However, the use of MC was not without concerns. The occurrence of medication overuse headaches (MOH) and adverse events, primarily mild, were noted in a significant portion of patients using oral cannabinoid preparations. These findings underscore the need for a cautious approach to using MC for migraine treatment.
The Current State of Medical Cannabis Research for Migraines
Despite the promising results, the studies reviewed were varied in methodology, and the overall quality of evidence was not robust enough to draw definitive conclusions. This highlights a critical gap in the research and the urgent need for more rigorous experimental studies to understand better the effectiveness and safety of MC in treating migraines.
Future Directions: The Path Forward
The potential benefits of MC for migraine relief are evident, yet the path to its widespread acceptance and use is fraught with challenges. Future research should focus on identifying the optimal routes of administration, determining effective dosages, and comparing MC with traditional migraine treatments. Such efforts will not only help establish MC as a viable treatment option but also ensure its safe and effective use among migraine sufferers.
Navigating the Use of Medical Cannabis for Migraines
For individuals considering MC for migraine treatment, it is crucial to consult with a healthcare professional if you use pharmaceuticals that could interact - generally, this is not an issue. This is particularly important given the variability in cannabis strains, potencies, and legal status across regions - most doctors are unaware of it's benefits so talking to them will help them learn.
Conclusion: A Promising Horizon
The exploration of MC as a treatment for migraines offers a glimmer of hope for those who have struggled to find relief through conventional means. While the initial evidence is encouraging, the journey toward fully understanding and integrating MC into migraine treatment protocols is ongoing.
As research continues to evolve, so too does the potential for MC to transform the lives of migraine sufferers worldwide, offering a new lease on life free from the debilitating grip of migraines.
© Mike Robinson, Global Cannabis Educator and Creator of ECS Balance Control, The Researcher OG
References:
1. Arnold M. Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. (2018) 38:1–211. doi: 10.1177/0333102417738202
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. (2017) 390:1211–59. doi: 10.1016/S0140-6736(17)32154-2
3. Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. Med Clin North Am. (2019) 103:215–33. doi: 10.1016/j.mcna.2018.10.003
4. Leimuranta P, Khiroug L, Giniatullin R. Emerging role of (Endo) cannabinoids in migraine. Front Pharmacol. (2018) 9:420. doi: 10.3389/fphar.2018.00420
5. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. (2019) 59:1–18. doi: 10.1111/head.13456
6. Gfrerer L, Guyuron B. Surgical treatment of migraine headaches. Acta Neurol Belg. (2017) 117:27–32. doi: 10.1007/s13760-016-0731-1
7. Jose A, Nagori SA, Roychoudhury A. Surgical management of migraine headache. J Craniofac Surg. (2018) 29:e106–8. doi: 10.1097/SCS.0000000000004078
8. Rehman T, Ahmad S, Fatima Q. Effects of dietary supplementations and herbs on migraine - a systematic review. J Complement Integr Med. (2019) 16. doi: 10.1515/jcim-2018-0143
9. Fasinu PS, Phillips S, ElSohly MA, Walker LA. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy Jul. (2016) 36:781–96. doi: 10.1002/phar.1780
10. Schnelle M GF, Reif M, Gorter RW. Results of a standardized survey on the medical use of cannabis products in the German-speaking areas. Forsch Komplementarmed. (1999) 6(Suppl. 3):28–36. doi: 10.1159/000057154
11. Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology. (2022). doi: 10.1007/s00213-021-06047-8 [Epub ahead of print].
12. (ADHS) ADoHS. Arizona Medical Marijuana Program October 2020 Monthly Report. ADoHS (2020).
13. Eagleston LRM, Kalani NK, Patel RR, Flaten HK, Dunnick CA, Dellavalle RP. Cannabinoids in dermatology: a scoping review. Dermatol Online J. (2018) 24. doi: 10.5070/D3246040706
14. Stetten N, Pomeranz J, Moorhouse M, Yurasek A, Blue AV. The level of evidence of medical marijuana use for treating disabilities: a scoping review. Disabil Rehabil. (2020) 42:1190–201. doi: 10.1080/09638288.2018.1523952
15. Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. (2019) 269:87–105. doi: 10.1007/s00406-019-00984-4
